IONS News and Press, Ionis Pharmaceuticals Inc. From 06/15/24

2024-06-15 15:37:28 ET The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%.... Read the full article on Seeking Alpha For further details see: ...

2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...

2024-05-31 22:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-31 07:46:06 ET More on Ionis Pharmaceuticals Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript Biogen also drops collaboration with Ionis on Angelman syndrome candidate ...

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema PR Newswire Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and ...

2024-05-30 17:30:28 ET More on Biogen Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen inks $1.8B deal to acquire immune drug developer HI-Bio B...

2024-05-28 16:39:10 ET Summary Ionis Pharmaceuticals' Q1 2024 earnings showed a loss of $143m, a larger loss than the $87m in the previous year. The company has a healthy cash balance of $2.2bn and expects revenues of +$575m in 2024, albeit with further heavy losses. Ionis has...

Ionis to hold donidalorsen Phase 3 data webcast PR Newswire Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , May 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will...

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) PR Newswire – Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and...